From the Departments of Anesthesia & Perioperative Medicine, University Hospital-LHSC, St. Joseph's Hospital, Schulich School of Medicine & Dentistry, Anesthesia & Perioperative Medicine, Schulich School of Medicine & Dentistry, St. Joseph's Hospital, Anesthesia & Perioperative Medicine, Victoria Hospital-LHSC, and Anesthesia & Perioperative Medicine and Epidemiology & Biostatistics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.
Anesth Analg. 2013 Sep;117(3):677-685. doi: 10.1213/ANE.0b013e31829cfd21. Epub 2013 Aug 6.
A single dose of epidural morphine is effective in reducing pain after cesarean delivery but is associated with adverse effects. In this study, we sought to establish whether half the traditional dose of epidural morphine, when administered as part of a multimodal analgesia regimen after cesarean delivery, was associated with noninferior analgesia and fewer adverse effects.
Ninety term parturients undergoing cesarean delivery under epidural anesthesia were enrolled in this randomized, double-blinded, noninferiority study. Patients were randomly allocated to receive either 3 mg epidural morphine or, half this dose, 1.5 mg epidural morphine. In addition, subjects received regular systemic ketorolac and acetaminophen. Rescue analgesia (oral oxycodone) was administered for breakthrough pain. The primary outcome was the difference between groups in total opioid consumption (measured in median IV morphine equivalents) within the first 24 hours. A prespecified noninferiority margin of 3.33 mg was used. Secondary outcomes included total opioid consumption from 24 to 48 hours, numerical rating scale pain scores, time to first request for analgesics, overall pain relief, maternal satisfaction, quality of recovery, and adverse effects.
Data were analyzed for 87 participants. Noninferiority was demonstrated as the difference in median 24-hour opioid consumption between the 1.5 mg epidural morphine (EM) and 3 mg EM groups was 0 mg (1-sided 95% confidence interval [CI], 2.5 mg), which was less than the prespecified noninferiority margin of 3.33 mg. No significant differences were found between groups in the median 24- to 48-hour opioid consumption or the median total opioid consumption within 48 hours. Pain scores, overall pain relief, and satisfaction at 24 and 48 hours were not significantly different between groups. The 1.5 mg EM group had a lower incidence of moderate and severe pruritus at 6 and 12 hours (relative risk [RR] 0.44, 95% CI, 0.2-0.9 and RR 0.41, 95% CI, 0.2-0.8, respectively) and had less nausea and vomiting at 6 hours (RR 0.22, 95% CI, 0.05-0.9). There was no difference in average pain scores at 12 weeks between the 2 groups.
When used as part of a multimodal analgesia regimen, 1.5 mg epidural morphine provided noninferior postcesarean analgesia and caused fewer adverse effects compared with 3 mg epidural morphine.
单次硬膜外吗啡剂量可有效减轻剖宫产术后疼痛,但与不良反应有关。在这项研究中,我们旨在确定剖宫产术后给予半传统剂量硬膜外吗啡(作为多模式镇痛方案的一部分)是否与非劣效性镇痛和较少不良反应相关。
本随机、双盲、非劣效性研究纳入了 90 例接受硬膜外麻醉下剖宫产术的足月产妇。患者被随机分配接受 3 mg 硬膜外吗啡或半剂量 1.5 mg 硬膜外吗啡。此外,受试者还接受常规的全身酮咯酸和对乙酰氨基酚。突破性疼痛时给予口服羟考酮补救镇痛。主要结局是两组在 24 小时内总阿片类药物消耗量(以中位数 IV 吗啡当量测量)的差异。使用了 3.33 毫克的预设非劣效性边界。次要结局包括 24 至 48 小时的总阿片类药物消耗量、数字评分量表疼痛评分、首次请求镇痛的时间、总体疼痛缓解、产妇满意度、恢复质量和不良反应。
对 87 名参与者进行了数据分析。24 小时内 1.5 mg 硬膜外吗啡(EM)和 3 mg EM 组之间的中位数阿片类药物消耗量差异为 0 毫克(单侧 95%置信区间[CI],2.5 毫克),低于预设的非劣效性边界 3.33 毫克。两组间 24 至 48 小时的中位数阿片类药物消耗量或 48 小时内的总阿片类药物消耗量无显著差异。两组间 24 小时和 48 小时的疼痛评分、总体疼痛缓解和满意度无显著差异。1.5 mg EM 组在 6 小时和 12 小时时出现中度和重度瘙痒的发生率较低(相对风险[RR]0.44,95%CI0.2-0.9 和 RR0.41,95%CI0.2-0.8),在 6 小时时恶心呕吐的发生率较低(RR0.22,95%CI0.05-0.9)。两组在 12 周时的平均疼痛评分无差异。
与 3 mg 硬膜外吗啡相比,在多模式镇痛方案中使用 1.5 mg 硬膜外吗啡可提供非劣效性剖宫产术后镇痛,并减少不良反应。